Chronic l-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra
- 1 March 2014
- journal article
- Published by Elsevier in Behavioural Brain Research
- Vol. 261, 79-88
Abstract
No abstract availableKeywords
Funding Information
- Polish MNiSW (N N401 647340)
This publication has 55 references indexed in Scilit:
- Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the diseaseBritish Journal of Pharmacology, 2011
- Evolution of Extra-Nigral Damage Predicts Behavioural Deficits in a Rat Proteasome Inhibitor Model of Parkinson's DiseasePLOS ONE, 2011
- Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's diseaseBMC Neuroscience, 2010
- Nigral Degeneration with Inclusion Body Formation and Behavioral Changes in Rats after Proteasomal InhibitionStereotactic and Functional Neurosurgery, 2009
- Hemiparkinsonian rats rotate toward the side with the weaker dopaminergic neurotransmissionBehavioural Brain Research, 2008
- MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in ratsNeuropharmacology, 2005
- Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibitionNeuroscience Letters, 2005
- α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodiesProceedings of the National Academy of Sciences, 1998
- Mutation in the α-Synuclein Gene Identified in Families with Parkinson's DiseaseScience, 1997
- Evidence that the substantia nigra is a site of action for l-DOPANeuroscience Letters, 1988